Studies on the effects of transcriptional regulation of INPP5D, SHIP1 blockade and more recently SHIP1/2 agonists are currently underway, with most studies showing promise, as they point to the fact that modulating the expression of SHIP1 and its paralog, SHIP2, may significantly improve disease phenotype and eventually provide novel therapeutic options for Alzheimer’s disease. This evidence concerns the gene INPP5D and early-onset autosomal dominant Alzheimer disease.